Mitapivat Disease Interactions
There are 2 disease interactions with mitapivat.
Mitapivat (applies to mitapivat) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Mitapivat undergoes extensive hepatic metabolism. The systemic exposure of mitapivat is expected to increase with moderate and severe liver dysfunction. Mitapivat should not be used in patients with moderate to severe liver dysfunction.
Mitapivat (applies to mitapivat) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effects of renal dysfunction on mitapivat pharmacokinetics were assessed with population pharmacokinetic analyses. There are limited data available in patients with estimated glomerular filtration rate (eGFR) 30 to less than 60 mL/min/1.73 m2 and no data available in patients with eGFR less than 30 mL/min/1.73 m2; caution is recommended in these patients.
Switch to professional interaction data
Mitapivat drug interactions
There are 380 drug interactions with mitapivat.
Mitapivat alcohol/food interactions
There are 2 alcohol/food interactions with mitapivat.
Report options
More about mitapivat
- mitapivat consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous metabolic agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
